A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 150 participants.

Also called NCT04680026

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 150 participants (planned count) (from the registry)
Sponsor
HUYABIO International, LLC. (from the registry)
Registry
  • NCT NCT04680026
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Bosnia & Herzegovina, Canada, New Zealand, Serbia (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04680026. Randomized; quadruple masking; primary purpose treatment. Start 2021-06-01 (actual); primary completion 2025-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of IV HBI-3000 for the Conversion Recent Onset Atrial Fibrillation (AF)
Intervention (Drug)
HBI-3000
Intervention (Drug)
Placebo
Lead sponsor
HUYABIO International, LLC. (class: industry)

Record details

Record id
cardio:ct-nct04680026
Content hash
d9e769c0930c3566acb0c70a3cc33b6a3ef819f9af044d75a3714c78e21ec293